Concept Life Sciences Opens New Facility to Offer Complete Pharmaceutical Manufacturing Support Services

Concept Life Sciences, a knowledge-based provider of integrated discovery, development and analytical services, has unveiled a new, state-of-the-art clinical and niche commercial facility to support pharmaceutical and biotechnology companies throughout the development and manufacture of active pharmaceutical ingredients (API).

Located at Discovery Park in Sandwich, UK, the purpose-built facility offers a comprehensive range of services designed to allow partner organisations to take drug candidates through discovery, scale up and into current Good Manufacturing Practice (cGMP)-compliant production.

“Pharmaceutical and biotech companies of all sizes are demanding high-quality, early-stage manufacturing capabilities that can readily scale up target molecules from grams to kilograms, and then into cGMP-compliant API manufacture all while mitigating the risk typically associated with moving between different stages of the drug development process,” said Dr Paul Doyle, Chief Scientific Officer at Concept Life Sciences. “Building on our depth of scientific expertise in medicinal and discovery chemistry, the new, specialist facility strengthens our support services so we can enable our partners to boost their productivity and deliver products to market faster and more efficiently.”

With the new facility joining the company’s growing network of sites across the UK, Concept Life Sciences’ pharmaceutical manufacturing support services now comprise:

  • API process research and development, and cGMP – both small- and larger-scale plants, including capability to provide demonstration, toxicology and clinical batches
  • Quality control release testing – a unique blend of high-end characterisation techniques and standard chromatographic methods for raw material and finished product release in compliance with cGMP requirements
  • Stability studies – in line with the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
  • Out-of-specification investigations – identification of contaminants and impurities, materials characterisation and responsiveness in emergencies to minimise production downtime
  • Extractables, leachables and sorption studies – testing of packaging to support regulatory submissions and packaging changes
  • Cleaning verification and validation – full cGMP-compliant capabilities to ensure optimal product protection
  • Occupational hygiene – sensitive surrogate testing using low-hazard compounds, air quality monitoring and safe handling of biological samples, as well as development, validation and analysis of air filter and swab samples
  • Environmental monitoring – effluent analysis, land contamination testing and emissions control

Further information about Concept Life Sciences’ pharmaceutical manufacturing support services can be found at

About Concept Life Sciences
Concept Life Sciences is a knowledge-based, science-led provider of integrated solutions to the pharmaceutical, biotechnology, agrochemical, petrochemical, chemical, food, environmental and consumer products industries. Our Integrated Discovery and Development Services division offers in-house scientific knowledge and expertise to support every stage of the discovery and development process of chemicals, from first concept and regulatory submission to the launch of a finished product. Through our Analytical Services division, we provide integrated services spanning routine monitoring and testing to specialist analysis.

With a commitment to problem-solving, quality, collaboration and flexibility, the Concept Life Sciences team of over 800 people, including more than 500 highly skilled, experienced scientists, supports our global customer base from 11 state-of-the-art laboratory facilities.

Having experienced rapid growth, Concept Life Sciences remains focused on problem solving, quality, collaboration, and flexibility. In January 2018, Concept Life Sciences became an Operating Company of Spectris plc. Further information can be found at

Advertisement - Oliver